Medicare Part D coverage · betamethasone dipropionate · RxCUI 833461
betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension
Per the CMS 2026 Part D formulary file, betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension is covered by 191 Medicare Part D plans (3.8% of enrollable products), averaging Tier 3.9, with prior authorization required on 28.6% of covering formularies.
- 3.8%
- Plan coverage
- 191
- Plans covering
- T3.9
- Avg tier
- 28.6%
- Prior auth required
What the CMS Formulary Data Shows for betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension
Per the CMS 2026 Part D formulary file, betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension (RxNorm concept RXCUI 833461, generic name betamethasone dipropionate) appears on 14 distinct formulary files spanning 191 Medicare Part D plan offerings - 3.8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 3 to Tier 5, with a cross-plan average of Tier 3.9.
Real-world access to betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension depends on utilization management as much as tier placement: 28.6% of covering formularies require prior authorization. 7.1% require step therapy. 21.4% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 407,711 Part D beneficiaries filled betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension in 2023, with total plan-and-beneficiary spending of $42,156,509 and an average per-beneficiary annual cost of $103.40. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension today.
Coverage Details
- Formularies covering
- 14
- Plans covering
- 191
- Coverage rate
- 3.8%
- Tier range
- Tier 3 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 28.6% of formularies
- Step therapy required
- 7.1% of formularies
- Quantity limits
- 21.4% of formularies
2023 Medicare Spending
- Beneficiaries
- 407,711
- Total spending
- $42,156,509
- Avg per beneficiary
- $103.40
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | UT |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | NV |
| Select Health Medicare Dual (HMO D-SNP) | Selecthealth, Inc. | T3 | No | $0 | UT |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | UT |
| Select Health Medicare + Kroger (HMO) | Selecthealth, Inc. | T3 | No | $0 | NV |
| Select Health Medicare + Kroger (HMO) | Selecthealth, Inc. | T3 | No | $0 | UT |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | CO |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | CO |
| Select Health Medicare + Kroger (HMO) | Selecthealth, Inc. | T3 | No | $0 | CO |
| Select Health Medicare Flex (HMO) | Selecthealth, Inc. | T3 | No | $0 | CO |
| Select Health Medicare + Kroger (HMO) | Selecthealth, Inc. | T3 | No | $0 | CO |
| Select Health Medicare Active (HMO) | Selecthealth, Inc. | T3 | No | $0 | CO |
| Select Health Medicare Dual (HMO D-SNP) | Selecthealth, Inc. | T3 | No | $0 | NV |
| Select Health Medicare Wellness (HMO) | Selecthealth, Inc. | T3 | No | $0 | NV |
| Healthy Mississippi Premier Advantage (HMO-POS) | Healthy Mississippi, Inc. | T3 | No | $0 | MS |
| Medicare BlueEssential (PPO) | Excellus Health Plan, Inc. | T4 | Yes | $0 | NY |
| Medicare BlueActive (PPO) | Excellus Health Plan, Inc. | T4 | Yes | $0 | NY |
| Medicare BlueVital (PPO) | Excellus Health Plan, Inc. | T4 | Yes | $0 | NY |
| Univera SeniorChoice Basic (HMO) | Excellus Health Plan, Inc. | T4 | Yes | $0 | NY |
| Univera SeniorChoice Extra (HMO) | Excellus Health Plan, Inc. | T4 | Yes | $0 | NY |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension covered by Medicare Part D?
Yes, betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension is covered by 191 Medicare Part D plans (3.8% of all Part D formularies).
What tier is betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension on Medicare Part D plans?
betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension averages Tier 3.9 across Part D plans, ranging from Tier 3 to Tier 5.
Does betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension require prior authorization?
28.6% of Part D formularies require prior authorization for betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension. Step therapy: 7.1%. Quantity limits: 21.4%.
How much does Medicare spend on betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension?
In 2023, total Medicare Part D spending on betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension was $42,156,509, covering 407,711 beneficiaries. The average spend per beneficiary was $103.40.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- brensocatib 10 MG Oral Tablet [Brinsupri] T3.9
- crinecerfont 25 MG Oral Capsule [Crenessity] T3.9
- {180 (danicopan 100 MG Oral Tablet [Voydeya]) } Pack [Voydeya 200 MG Dose Bottle] T3.9
- {90 (danicopan 100 MG Oral Tablet [Voydeya]) / 90 (danicopan 50 MG Oral Tablet [Voydeya]) } Pack [Voydeya 150 MG Dose Bottle] T3.9
- sofosbuvir 400 MG / velpatasvir 100 MG Oral Tablet T3.9
- cysteamine 3.8 MG/ML Ophthalmic Solution [Cystadrops] T3.9